Genedrive plc (LSE:GDR), a developer of rapid genetic testing solutions for point-of-care healthcare, has secured funding of approximately £5.26 million before expenses through a combination of share placing, subscriptions, an open offer and a loan conversion.
The open offer raised about £0.91 million and was taken up by 60.7% of eligible shareholders, while a further £0.35 million came from additional subscriptions by investors who were unable to fully participate in the earlier placing or offer. When combined with the firm and conditional subscriptions, placing and loan conversion, the total fundraising is expected to generate around £4.9 million in net proceeds, subject to shareholder approval and the admission of 515,964,264 new shares. Following issuance, the company’s total share count will rise to 1,605,568,256.
Notable shareholders David Nugent and Robert English participated in the expanded fundraising round. Chief executive Dr. Gino Miele and chief financial officer Russ Shaw also subscribed through the open offer as related parties, with the board stating—after consulting its advisers—that their involvement was fair and reasonable for shareholders.
Genedrive intends to use the strengthened capital position to advance its commercial strategy in point-of-care pharmacogenetics, supporting the rollout of its testing platform and expanding adoption of its key diagnostic kits.
From an outlook perspective, the company continues to face challenges linked to persistent operating losses, ongoing cash burn and a reduced equity base, although it carries minimal debt. Technical indicators are somewhat supportive, with the share price trading above key moving averages and a positive MACD reading, though a high RSI suggests potential near-term overbought conditions. Valuation remains difficult to assess due to negative earnings and a corresponding negative price-to-earnings ratio.
More about Genedrive
Genedrive plc is a UK-based developer of rapid pharmacogenetic tests designed to guide personalised treatment decisions at the point of care, particularly in time-critical clinical environments. Its flagship products include the Genedrive MT-RNR1 ID Kit, used to help guide antibiotic treatment in newborns, and the Genedrive CYP2C19 ID Kit. Both run on the company’s proprietary thermocycler platform and use single-use, ambient-stable cartridges that remove the need for cold-chain logistics while enabling fast, low-cost genetic testing.
Leave a Reply